LTR Pharma signs deal to deliver 150,000 ROXUS units
Share
- LTR Pharma (ASX:LTP) executed a definitive commercial agreement with U.S. telehealth platform Shed Holdings.
- Shares in LTR Pharma were up 9.09% at $0.54 following the announcement.
- She'd committed to supporting the delivery of at least 150,000 ROXUS units in the U.S. during the first 12 months post-launch.
LTR Pharma (ASX:LTP) has executed a definitive telehealth distribution agreement with U.S. platform Shed Holdings to commercialise ROXUS.
The deal converts a previously signed binding term sheet into a comprehensive long-form commercial agreement for the planned U.S. market launch.
The source document did not contain executive quotes regarding the agreement.
Under the terms of the deal, Shed committed to supporting the delivery of not less than 150,000 ROXUS units during the first 12 months following its commercial launch.
The execution allows both entities to finalise remaining operational and implementation steps ahead of the planned U.S. commercial rollout.
Following the announcement, the LTR Pharma share price was up at $0.54.
Shed will commercialise the treatment through its dedicated men's health platform, Mavrox, as well as via its main consumer website.
The agreement forms part of LTR Pharma's ongoing strategy to commercialise its treatments through established health partners in the U.S. market.
